Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V2 receptor agonists

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 21, 2008, Pages 9524-9535

  Tsukamoto, Issei ^a   Koshio, Hiroyuki ^a   Akamatsu, Seijiro ^a   Kuramochi, Takahiro ^a   Saitoh, Chikashi ^a   Yatsu, Takeyuki ^a   Yanai Inamura, Hiroko ^a   Kitada, Chika ^a   Yamamoto, Eisaku ^a   Sakamoto, Shuichi ^a   Tsukamoto, Shin ichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

(4,4 Difluoro 1,2,3,4 tetrahydro 5H 1 benzazepin 5 ylidene)acetamide derivatives; Urine volume; V2 receptor agonist; V2 receptor antagonist

Indexed keywords

(4,4 DIFLUORO 1,2,3,4 TETRAHYDRO 5H 1 BENZAZEPIN 5 YLIDENE)ACETAMIDE DERIVATIVE; 2 [1 [2 CHLORO 4 (3 METHYL 1H PYRAZOL 1 YL)BENZOYL] 4,4 DIFLUORO 1,2,3,4 TETRAHYDRO 5H 1 BENZAZEPIN 5 YLIDENE] N (PYRIDIN 2 YLMETHYL)ACETAMIDE; 2 [1 [2 CHLORO 4 (3 METHYLPYRROLIDIN 1 YL)BENZOYL] 4,4 DIFLUORO 1,2,3,4 TETRAHYDRO 5H 1 BENZAZEPIN 5 YLIDENE] N (PYRIDIN 2 YLMETHYL)ACETAMIDE; ACETAMIDE DERIVATIVE; BENZAZEPINE DERIVATIVE; HORMONE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; VASOPRESSIN V2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIURESIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ANALYSIS; WATER LOADING;

ANIMALS; ANTIDIURETIC AGENTS; ARGININE VASOPRESSIN; BENZAZEPINES; CHO CELLS; CRICETINAE; CRICETULUS; MALE; MOLECULAR STRUCTURE; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 53749090571     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.09.039     Document Type: Article

References (16)

1. Hardman J.G., and Limbird L.E. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. (2001), McGraw-Hill, New York pp 789-944
2. Guyton A.C., and Hall J.E. Textbook of Medical Physiology. 9th ed. (1999), W.B. Saunders, Medina pp 933-944
3. Michel R.H., Kirk C.J., and Billah M.M. Biochem. Soc. Trans. 7 (1979) 861
4. Laszlo F.A., Laszlo F., and De Weid D. Pharmacol. Rev. 43 (1991) 73
5. Kondo K., Ogawa H., Shinohara T., Kurimura M., Tanada Y., Kan K., Yamashita H., Nakamura S., Hirano T., Yamamura Y., Mori T., Tominaga M., and Itai A. J. Med. Chem. 43 (2000) 4388
6. Kondo K., Kan K., Tanada Y., Bando M., Shinohara T., Kurimura M., Ogawa H., Nakamura S., Hirano T., Yamamura Y., Kido M., Mori T., and Tominaga M. J. Med. Chem. 45 (2002) 3805
7. Venkatesan A.M., Grosu G.T., Failli A.A., Chan P.S., Coupet J., Saunders T., Mazandarani H., and Ru X. Bioorg. Med. Chem. Lett 15 (2005) 5003
8. Failli A.A., Shumsky J.S., Steffan R.J., Caggiano T.J., Williams D.K., Trybulsky E.J., Ning X., Lock Y., Tanikella T., Hartmann D., Chan P.S., and Park C.H. Bioorg. Med. Chem. Lett. 16 (2006) 954
9. Taniguchi, N.; Tanaka, A.; Matsuhisa, A.; Sakamoto, K.; Koshio, H.; Yatsu, T. Patent WO 9506035, 1995; Chem. Abstr. 1995, 123, 228010.
10. Sudborough J.J. J. Chem. Soc. 67 (1895) 601
11. Katritzky A.R., Pilarski B., and Urogdi L. Synthesis (1989) 949
12. Shimada Y., Akane H., Taniguchi N., Matsuhisa A., Kawano N., and Tanaka A. Chem. Pharm. Bull. 53 (2005) 589
13. Tahara A., Saito M., Sugimoto T., Tomura Y., Wada K., and Kusayama T. Br. J. Pharmacol. 125 (1998) 1463
14. Tahara A., Saito M., Sugimoto T., Tomura Y., Wada K., Kusayama T., Tsukada J., Ishii N., Yatsu T., Uchida W., and Tanaka A. Br. J. Pharmacol. 125 7 (1998) 1463
15. Lazareno S., and Bridsall N.J. Br. J. Pharamacol. 109 (1993) 1110
16. Takasaki J., Kamohara M., Saito T., Matsumoto M., Matsumoto S., Ohishi T., Soga T., Matsushime H., and Furuichi K. Mol. Pharmacol. 60 3 (2001) 432